- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BIIB
Recent news which mentions BIIB
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
Roche's Follicular Lymphoma Therapy Scores FDA Approval
December 23, 2022
From Benzinga
3 Nasdaq Stocks That Are Up 25% in 3 Months
December 23, 2022
From Motley Fool
1 Green Flag and 1 Red Flag for Biogen
December 23, 2022
From Motley Fool
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
From Benzinga
Has This Top Pharma Company Found Its Next Billion-Dollar Product?
December 22, 2022
From Motley Fool
Ahead of a year of big unknowns, here are two sectors investors should consider, says this money manager
December 22, 2022
From MarketWatch
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
From InvestorPlace
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move
December 18, 2022
From Motley Fool
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
December 18, 2022
From Motley Fool
Eating these simple foods may slow Alzheimer’s by a third
December 16, 2022
From MarketWatch
New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’
December 09, 2022
Tickers
BIIB
From MarketWatch
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
December 08, 2022
From Motley Fool
Why 2023 Could Be a Big Year for Biogen
December 07, 2022
From Motley Fool
Even After This Year’s Melt-Up, Runway Remains for LLY Stock
December 05, 2022
From InvestorPlace
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
From Motley Fool
From MarketWatch
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
From Benzinga
5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners
November 30, 2022
From MarketWatch
CrowdStrike (CRWD) Stock Sinks on Weak Guidance
November 30, 2022
From InvestorPlace
BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen
November 30, 2022
Tickers
BIIB
From InvestorPlace
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
From Benzinga
Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday
November 30, 2022
From Benzinga
Banks are short more than $1 trillion in capital, this analyst says, who fears the shortfall will only get worse
November 30, 2022
From MarketWatch
A new Alzheimer’s treatment may help some patients, though researchers say more safety data is needed
November 29, 2022
Tickers
BIIB
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.